Source: Eur Respir J 2011; 37: 1104-1118
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Dumitrascu R., Kulcke C., Königshoff M., Kouri F., Yang X., Morrell N., Ghofrani H.A., Weissmann N., Reiter R., Seeger W., Grimminger F., Eickelberg O., Schermuly R.T., Pullamsetti S.S.. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats. Eur Respir J 2011; 37: 1104-1118

Member's Comments

No comment yet.

Related content which might interest you: Apoptosis and cell proliferation in chronic hypoxic pulmonary hypertension Source: Lung Science Conference 2007 - Translational research in pulmonary disease: Hypoxia-driven mechanisms Year: 2007 Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition Source: Eur Respir J 2008; 31: 599-610 Year: 2008 2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension Year: 2007 PDGF promotes pulmonary artery smooth muscle cell proliferation and migration in pulmonary arterial hypertension Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats Source: Eur Respir J 2011; 37: 813-822 Year: 2011 In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension Year: 2007 Pulmonary hypertension: the science behind the disease spectrum Source: Eur Respir Rev 2012; 21: 19-26 Year: 2012 Inhibition of the Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation Source: Annual Congress 2006 - Pulmonary circulation: inflammation and remodelling Year: 2006 Involvement of FHL1 in vascular remodelling Source: Annual Congress 2006 - Lung vascular and parenchymal remodeling Year: 2006 Anti-fibrotic effects of pirfenidone on pulmonary arterial vascular smooth muscle cells Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 Inflammation in pulmonary arterial hypertension Source: Eur Respir J 2003; 22: 358-363 Year: 2003 Pathobiology of pulmonary arterial hypertension Source: Eur Respir J 2002; 20: 1559-1572 Year: 2002 Mast cells promote lung vascular remodelling in pulmonary hypertension Source: Eur Respir J 2011; 37: 1400-1410 Year: 2011 Shroom expression is attenuated in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 871-880 Year: 2008 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 IL-6 receptor overexpression in pulmonary arterial smooth muscle cells in idiopathic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 VEGF reduces pulmonary hypertension and vascular remodeling in pulmonary fibrosis through reduced endothelial apoptosis Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension Source: Annual Congress 2011 - Treatment of human pulmonary hypertension Year: 2011